Summary & Overview
HCPCS Q9953: Iron-Based MRI Contrast Injection, Per mL
HCPCS Level II code Q9953 identifies an iron-based magnetic resonance contrast agent billed per milliliter for use in MRI procedures. This code matters nationally as MRI contrast agents are integral to diagnostic imaging workflows, affecting imaging accuracy, care pathways, and payer coverage decisions. Accurate coding for contrast agents influences billing clarity, utilization tracking, and reimbursement for facilities that perform MRI studies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary outlines payer coverage considerations and common modifiers that may appear on claims, while noting that some input fields are not available. Readers will learn the clinical context for using iron-based MRI contrast, typical sites of service, and what to expect in payer interactions. The publication also provides benchmarking and policy context where available, including national reimbursement patterns and programmatic notes relevant to imaging providers and billing staff.
This resource is intended for a national audience and focuses on the code definition, clinical application, and the payer landscape relevant to facilities and practitioners that administer MRI contrast agents.
Billing Code Overview
HCPCS Level II code Q9953 describes an injection, iron-based magnetic resonance contrast agent, per ml. This code represents the billed unit for administering an iron-based contrast agent used to enhance magnetic resonance imaging (MRI) studies.
Service type: Diagnostic radiology contrast administration
Typical site of service: Outpatient imaging centers, hospital radiology departments, and ambulatory care settings where MRI scans are performed
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged adult referred for an abdominal or pelvic magnetic resonance imaging (MRI) exam to evaluate liver lesions, focal nodular hyperplasia, or characterization of a suspected tumor identified on ultrasound or CT. The radiology team prepares the patient in an outpatient imaging center or hospital radiology department. The injection of the iron-based magnetic resonance contrast agent (Q9953) is performed by a credentialed provider (radiologist, interventional radiologist, or qualified advanced practice provider) or an authorized registered nurse under established protocols. Prior to injection, the patient undergoes screening for contraindications (iron allergy, severe renal impairment if relevant to agent labeling), informed consent, and IV access placement. The contrast dose is calculated based on the agent concentration and the planned imaging sequences. The barcode or vial volume is documented; billing reports use per-milliliter units for Q9953. The MRI sequences are acquired immediately after contrast administration per institutional protocol for lesion enhancement characterization. Post-procedure monitoring is brief, focused on allergic reaction surveillance and IV site status. The typical site of service is an outpatient imaging center or hospital outpatient radiology department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |